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It is not known whether the histopathology of the 
liver allograft can be predicted from biochemical 
measurements in serum with the same cofidence as in 
the native liver. To answer this question we compared 
the histopathological diagnoses in 170 biopsy spec- 
imens from 70 adult transplant recipients obtained 
during the first 180 days, with the concentrations of the 
serum bilirubin and the activities of AST, ALT and 
alkaline phosphatase measured at the same time. The 
most frequent diagnosis was cholestasis (n = 451, 
which was mild, moderate or severe and which may 
have been complicated by rejection (n = 28) or 
ischemia (n = 14). Hepatitis (n = 14), ischemia with 
rejection (n = 6) and spotty focal necrosis (n = 6) were 
diagnosed less frequently. Fifteen biopsy specimens 
were reported as histopathologically normal. In 
general, biochemical measurements discriminated 
poorly between different histopathological diagnoses. 
The histopathologically normal liver often showed an 
abnormal pattern of enzymes and an increase in the 
serum bilirubin level. As a result histopathologically 
normal biopsy specimens were indistinguishable bio- 
chemically from those with hepatitis. When two patho- 
logical conditions were found to coexist (e.g., 
cholestasis with either rejection or ischemic necrosis, 
or ischemic necrosis with rejection), the effect on the 
serum biochemistry was usually not additive and in 
some instances returned the biochemical abnormal- 
ities toward normal. With the exception of the serum 
bilirubin level, which increased with the severity of 
uncomplicated cholestasis, we could not identify a 
specific pattern of biochemical changes corresponding 
to a given histopathological diagnosis. We suggest that 
until more specific noninvasive methods of monitoring 
the transplanted liver are developed protocol liver 
biopsies offer the best means of identifying significant 
pathological conditions in liver allografts. (HEPA- 
TOLOGY 1992;16:688-693.) 
In 1983 transplantation was recognized as an ac- 
ceptable treatment for many forms of potentially fatal 
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liver disease (1). In addition to postoperative complica- 
tions, acute rejection was considered to be a major factor 
that could prevent a successful outcome (2-4). Rejection 
was then suspected on the basis of changes in bio- 
chemical measurements in serum. These measurements 
were also used to monitor the response to increased 
immunosuppression. In these earlier studies, the histo- 
pathological findings, when obtained, were considered 
supportive of the diagnosis. Snover et al. (5 )  provided a 
detailed histopathological description of acute cellular 
rejection consisting of the triad of mixed portal infil- 
trates, ductitis and endotheliitis. It was also recognized 
that the clinical suspicion of rejection could not always 
be confirmed by biopsy specimen. In recognition of this 
divergence, protocol biopsy specimens have been used 
routinely in many transplant centers including ours. We 
have been reluctant to diagnose and treat rejection on 
the basis of these findings without histopathological 
documentation and have been surprised to find rejection 
without any changes in biochemical data. These obser- 
vations prompted us to ask whether in the transplanted 
liver a specific relationship exists between the histo- 
pathological diagnosis and associated biochemical 
changes in serum, and whether, therefore, the histo- 
pathological interpretation of the allograft can be pre- 
dicted with the same confidence as in the native liver. We 
have studied the concentration of the serum bilirubin 
and the activities in serum of the aminotransferases and 
alkaline phosphatase because these are known to re- 
spond rapidly to changes in liver function. 
PATIENTS AND METHODS 
The data from all patients ages 18 years or older who had 
transplants between March 1, 1989, and April 16, 1990, were 
analyzed. This coincided with the addition of 3 mmoVL re- 
duced glutathione to the University of Wisconsin solution in all 
patients (6) and preceded the initiation of intravenous pros- 
taglandin E, in subsequent patients (7). Data were collected for 
up to 180 days after transplant. 
The protocol provided for liver biopsies to be performed at 
7, 14 and 21 days postoperatively unless the patient had died 
or had been discharged or if a biopsy was contraindicated for 
medical reasons. Additional liver biopsies were performed 
when clinically indicated. The histopathological diagnoses 
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FIG. 1. Choleatasis. The hepatocytes are swollen with rarified cytoplasm that appears finely granular or stringy. Arrows point to two dilated 
canaliculi containing biliary material. (Original magnification x 330. ) 
F'IG. 2. Acute cellular rejection. This portal tract is expanded by a dense inflammatory cellular infiltrate, many of which are small lymphocytes, 
but scattered immunoblasts and some neutrophils are present. Arrow points to the remains of a duct that is invaded by lymphocytes and that 
contains holes in its epithelium. (Original magnification x 330.) 
were recorded and compared with the total serum bilirubin inpatients these dmgnoses were almost always obtained just 
level (normal range = 0.2 to 0.9 mg/dl), AST (normal before biopey, and in a few instances they were obtained on the 
range = 0 to 45 ILJL), ALT (normal range = 0 to 45 IU/LJ and day before biopsy. In outpatients, laboratory studies were 
alkalinephosphatase (AP) (normal range = 30 to 130 IU/L). In usually obtained less than 24 to 36 hr before the biopsy. When 
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FIG. 3. Spotty lobular necrosis, part of the lobular hepatitis spectrum. In the center of the field is a cluster of lymphocytes that surround three 
fragments of necrotic hepatocyte cytoplasm seen as the dark rounded blobs. The surrounding hepatocytes are enlarged, and the cord pattern 
is obliterated. (Original magnification x 413.) 
the intervals between laboratory determination and biopsy 
exceeded 72 hr, the biopsy specimen was excluded from 
analysis. 
The postoperative immunosuppression program provided 
for the administration of azathioprine (1 mg/kg/day). On the 
day of transplant 500 mg of methylprednisone was given, 
followed by 50 mg of methylprednisone every 6 hr on the first 
postoperative day. The dose of prednisone was then tapered to 
30 mg/day on the 21st posttransplant day. Minnesota antilym- 
phoblast globulin (20 mg/kg/day) was begun on the first 
postoperative day. When the serum creatinine was less than 
3 mg/dl, cyclosporine administration was begun with an initial 
oral dose of 14 mg/kg/day and adjusted to a dosage mainte- 
nance level of 125 to 150 ng/ml. Minnesota antilymphoblast 
globulin therapy was stopped after at least 5 days and on the 
third day of cyclosporine treatment. Patients also received 
sulfamethoxazole with trimethoprim and acyclovir routinely 
during the first 30 days. 
Histopathological criteria of diagnoses are listed in Table 1. 
Statistical analysis was performed by t test. Unless oth- 
erwise stated, differences between means when described in 
the text were statistically significant at p < 0.025. The study 
was approved by the Institutional Review Board of the 
University of Michigan Medical School. 
RESULTS 
The analysis was based on 170 biopsy specimens from 
70 patients, including 3 patients who required that 
retransplantation be performed. These three patients 
underwent their first transplant before April 1, 1989. 
Another 11 patients could not undergo biopsies because 
of medical reasons and were therefore excluded from 
analysis. A total of 113 biopsy specimens were obtained 
during the first 30 postoperative days. Because the 
biochemical expression of the different histopathological 
diagnoses may have changed with the time elapsed since 
the transplant, the laboratory data from days 1 to 30 in 
each diagnostic category were compared with those from 
days 31 to 180. These were found to be indistinguishable 
and could therefore be combined. The sole exception was 
the serum bilirubin level in patients with normal biopsy 
specimens. This was 2.67 & 0.37 mg/dl (n = 10) for days 
1 to  30 and 1.2 k 0.2 mg/dl (n = 5) for days 31 to 180 
(p < 0.025). Comparison of serum bilirubin values 
between histopathologically normal and abnormal 
biopsy specimens was therefore not possible. The total 
serum bilirubin showed the expected fraction of conju- 
gated bilirubin. 
The biochemical data associated with biopsy spec- 
imens showing rejection differed from those showing 
inconclusive evidence of rejection by less than the S.E.M. 
when the two data were combined. They are therefore 
presented jointly. In contrast, biopsy specimens showing 
cholestasis exhibited biochemical patterns that differed 
according to the degree of histopathological severity and 
were therefore recorded separately. The laboratory data 
listed according to the most histopathological diagnoses 
made most frequently are summarized in Table 2. 
Eighteen different diagnoses accounted for the re- 
maining 32 biopsy specimens (including 2 showing 
rejection and 2 showing incomplete rejection). These 
were not separately evaluated. 
Choiestasis was the most commonly found abnor- 
mality and was described as mild in 19 patients, 
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moderate in 15 patients and severe in 11 patients. The 
serum bilirubin level increased with the severity of 
cholestasis. Levels of AST, although lower in patients 
showing mild cholestasis, did not discriminate between 
moderate and severe cholestasis. The intensity of 
cholestasis was not reflected in the activities of ALT or 
alkaline phosphatase. 
Rejection was the most common accompaniment of 
cholestasis and occurred in 7, 10 and 11 patients with 
mild, moderate or severe cholestasis, respectively. In 
patients with mild cholestasis acute cellular rejection 
resulted in modest increases in the serum bilirubin and 
aminotransferase values, but the alkaline phosphatase 
activity remained statistically unchanged when com- 
pared with patients whose biopsy specimens showed 
mild cholestasis without rejection. The effect of rejection 
on patients with moderate or severe cholestasis was 
unexpected. A decrease occurred in the activity of AST, 
and no significant change occurred in the remaining 
parameters. Rejection complicating ischemic necrosis 
was seen in six patients, again without significant 
changes compared with uncomplicated ischemia. Re- 
jection did not modify the biochemical patterns of 
patients with hepatitis. 
Histological appearances suggestive of ischemia were 
associated with cholestasis in a total of 14 patients. 
Ischemia lowered the serum bilirubin level among 
patients with moderate or severe cholestasis, and a 
similar trend, although statistically not significant, was 
shown by patients with mild cholestasis. Patients with 
moderate cholestasis plus ischemia showed an increase 
in AST. A less marked increase in ALT was seen in 
patients with mild or moderate cholestasis (p < 0.05). 
Biochemical studies did not consistently discriminate 
between different histopathological abnormalities. Thus 
patients with hepatitis had lower serum bilirubin con- 
centrations than patients with mild moderate or severe 
cholestasis. The aminotransferase activities were 
similar except for an increased AST activity in patients 
with hepatitis compared with those showing mild 
cholestasis. In contrast the activities of both ami- 
notransferases was lower in patients with hepatitis than 
in those with moderate or severe cholestasis. These two 
conditions, however, had their peak incidence on dif- 
ferent days. The median date of onset of hepatitis was 
100 days after transplant, whereas cholestasis occurred 
with a median date of onset on the 15th postoperative 
day. 
The enzyme pattern of patients with mild or severe 
cholestasis was indistinguishable from that of patients 
with uncomplicated ischemia. 
Six patients were reported as showing spotty focal 
necrosis. This was biochemically indistinguishable from 
mild cholestasis and could be differentiated from un- 
complicated hepatitis only by a modest increase in ALT 
(p < 0.05). Ischemia was associated with a higher serum 
bilirubin level than patients with hepatitis or spotty 
focal necrosis. 
The 15 patients with normal biopsy specimens were 
often not normal biochemically. Many had increased 
TABLE 1. Histopathological criteria for the most 
frequent diagnoses 
Histopathological Description DiagnOSeS 
Cholestasis 
(Fig. 1) 
Swelling and bile staining of central 
zone hepatocytes. 
Presence of bilirubin in dilated central 
zone canaliculi 
Periportal and periductal proliferation. 
Periportal, predominantly neutro- 
philic infiltrate, Pseudoxanthomas. 
Intensity of the changes were de- 
scribed as mild, moderate or severe, 
and if not specified otherwise they 
were considered to be moderate. 
Diagnosed as described by Snover et 
al. (5). Presence of mixed cellular in- 
filtrate expanding the portal tract 
with ductitis and endotheliitis. The 
infiltrate contains lymphocytes, plasma 
cell, immunoblasts, eosinophils and 
neutrophils. If one of these criteria 
was absent (generally ductitis) or 
modest in extent (generally the infil- 
trate), the diagnosis was reported as 




Central zone confluent necrosis with col- 
lapse with little inflammatory reaction. 
Ischemia 
This included some biopsy specimens 
Parenchymal disorganization, necrotic Hepatitis 
hepatocytes (single or in clusters). 
Sinusoidal lymphocytosis, Kupffer cell 
activation. This is usually accompa- 
nied by portal lymphocytosis but not 
by the mixed portal infiltrate found 
in rejection. 
Patchy necrotic hepatocytes within the 
lobules including scattered debris- necrosis 
laden phagocytes associated with de- (Fig. 3) 
fects in the hepatocyte cords. Ab- 
sence of lobular lymphocytosis. 
Normal 
with diffuse hypertrophy of the hepatocytes. 
spotty focal 
activities of AST transferase and alkaline phosphatase, 
and most of them had significantly elevated levels of 
ALT, which increased to an average of more than four 
times the upper limit of normal. The levels of this 
enzyme, therefore, did not discriminate between normal 
patients and patients with hepatitis, cholestasis (regard- 
less of severity), ischemia, or spotty focal necrosis. 
To determine whether the difference between patients 
may have masked a more predictable pattern in the same 
patients, we examined the records of patients having five 
or more biopsies. The correlation within patients was 
not better than between patients. An example is re- 
corded in Table 3. 
DISCUSSION 
In the native liver it is usually possible to discriminate 
between the histopathologically normal and those biopsy 
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TABLE 2. Laboratory values by diagnoses" 
Diagnoses Bilirubin (rnddl) AST (IU/L) ALT tIU/L) AP (N/L) 
Normal (n = 15) 
Cholestasis (mild) (n = 19) 
Cholestasis (moderate) (n = 15) 
Cholestasis (severe) (n = 11) 
Cholestasis (mild) + rejection (n = 7) 
Cholestasis (moderate) + rejection (n = 10) 
Cholestasis (severe) + rejection (n = 11) 
Hepatitis (n = 14) 
Hepatitis + rejection (n = 7) 
Ischemic necrosis (n = 14) 
Cholestasis (mild) + ischemic necrosis 
(n = 4) 
Cholestasis (moderate) + ischemic ne- 
crosis (n = 5) 
Cholestasis (severe) + ischemic necro- 
sis (n = 5) 
Ischemic necrosis + rejection (n = 5) 
Spotty focal necrosis (n = 6) 
2.1 2 0.30 
4.38 t 0.90 
3,4,5, (81, 10 
10.6 f 1.53 
2,4, 12,8, 10, 15 
23.5 f 4.1 
2,3, 13, 10, 15 
11.8 t 3.9 
2 
7.64 t 1.0 
17.0 t 3.3 
2.34 t 0.64 
1.81 f 0.27 
(2), 3, 10 
7.99 t 2.2 
2,3,4,8,  15 
3.1 f 0.47 
5.12 f 0.80 
3 
11.44 t 3.0 
4 
5.47 2 1.56 
3.48 t 0.59 
3,4, 10 
88 t 22 
2 (3),4, 10 
49 f 6.2 
3,4,5,6,8,  10, 1 
292 t 103 
2,12,8, 15, 1 
331 t 93 
2,8, 15, 1 
217 t 128 
2 
77 f 11 
2 
117 t 28 
102 f 12.4 
2,3,4 
99 f 27 
180 t 48 
2,15, 1 
135 2 55 
690 f 99 
3 
140 f 21 
208 f 90.5 
70 t 15 
3,4, 10 
225 f 60 
168 f 33 
(5) (11) 
280 f 72 
8 (12) 
291 f 53 
8 
326 2 119 
(2) 
253 f 38 
288 f 98 
134 f 21.6 
3,4, (15) 
190 f 33 
271 f 115 
322 t 100 
(2) 
777 t 418 
(3) 
267 f 67 
257 2 96 
214 t 32 
(8) 
138 f 19 
2, (3), 4, 10, 15 
269 f 42 
10 , l  
298 f 79 
(1) 
259 f 34 
1 
181 f 37 
307 t 44 
240 f 48 
191 f 26 
(9), 10 
358 t 104 
(8) 1 
393 f 79 
2 ,8 ,1  
182 f 34 
316 ? 88 
254 t 68 
484 ? 148 
291 f 78 
1 
Ap = alkaline phosphatase. 
"Data expressed as mean t S.E.M. The diagnoses are listed numerically in the first column on the left. The numbers below the data indicate 
statistically significant differences (p < 0.025) from the mean of the corresponding data in the diagnostic category so identified. For numbers 
in parentheses the differences are significant at p < 0.05. 
specimens showing hepatitis or cholestasis, with some 
confidence. Our data shows that in general this does not 
apply to the transplanted liver during the first 180 
postoperative days. In fact, the biochemical patterns 
shown in Table 2 are more notable for their similarities 
than for their differences. The only difference between 
groups that is both statistically significant and suffi- 
ciently striking to be clinically helpful is the association 
between increased levels of the serum bilirubin and the 
severity of cholestasis. In contrast cholestasis was 
associated with modest and generally nondiscriminatory 
increases in the serum alkaline phosphatase. None of the 
enzymes differentiated the normal from the patient with 
histological hepatitis. 
In the native liver, when two different types of injury 
are present, the corresponding biochemical pattern 
would be expected to be more abnormal than when each 
type of injury was found alone. This was often not true 
for the transplanted liver. Acute cellular rejection 
increased the serum bilirubin level only in patients with 
mild cholestasis, whereas enzyme activities increased 
little if at all. Acute cellular rejection did not modify the 
enzyme pattern in patients with hepatitis except for a 
modest increase in the alkaline phosphatase level, 
which, however, was statistically indistinguishable from 
13 of the 15 conditions listed in Table 2. When 
cholestasis was associated with ischemic necrosis the 
biochemical findings were even more surprising because 
ischemic necrosis appeared to lower the serum bilirubin 
level. Conversely, if cholestasis were regarded as a 
complication of ischemic necrosis this complication 
could not be predicted from measurements in serum. 
One consequence of these observations is that changes 
in biochemical measurements could be easily misinter- 
preted. Thus a fall in the serum bilirubin level in 
patients with moderate-to-severe cholestasis does not 
necessarily indicate resolution. It may equally well 
suggest superimposed rejection (8) or ischemic necrosis. 
The unexpected similarities of the biochemical 
pattern in patients with hepatitis and those whose 
biopsy specimens were reported as normal is the 
consequence of two factors: marked enzyme elevations 
that are sometimes seen in acute hepatitis were not seen 
here, whereas the patients with normal biopsy spec- 
imens showed a range of biochemical abnormalities 
substantially greater than that usually considered to be 
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TABLE 3. Histouatholodcal diagnoses and biochemical data in one patient 
Day after 
transplantation Diagnosis Bilirubin (mg/dl) AST CIUL) ALT CIU/L) AP CWL) 
10 Mild cholestasis 3.6 140 495 275 
12 Moderate cholestasis 20.9 209 194 188 
30 Mild acute rejection 2.7 61 95 926 
37 Resolving central necrosis 1.9 50 78 1004 
78 Expanding central necrosis 1.9 113 225 503 
110 Mild acute rejection 2.4 226 369 72 1 
Old ischemic necrosis 
Resolving central necrosis 
No rejection 
Smoldering hepatitis 
(?Resolving) chronic cholestasis, per- 
sistent central zone necrosis 
116 Mild portal inflammation 4.0 346 65 1 699 
Expanding confluent necrosis 
128 Extensive confluent necrosis 
More severe 
156 Ongoing central necrosis 
7.7 116 165 837 
20.8 185 148 685 
AP = Alkaline phosphatase 
normal. The two enzyme patterns therefore converged. 
One implication of this finding is that routine bio- 
chemical studies cannot be relied on to diagnose hepa- 
titis in ongoing or projected studies of the incidence of 
hepatitis after transplantation. 
This study required that patients were sufficiently 
well compensated to permit a liver biopsy. Data cannot 
therefore be extended to those patients, often with 
advanced liver failure, who could not be included in this 
report. We also could not define the biochemistry of 
uncomplicated rejection because this was only seen in 
four patients, and two of these patients had rejections 
that were reported as incomplete. Our study was also 
based on the assumption that the liver biopsy is the 
“gold standard” in the evaluation of the organ after 
transplantation. Even the normal liver is quite hetero- 
geneous (91, and, for reasons already stated, the trans- 
planted liver may be even more so. Rejection, too, may 
be found in only one portal triad, whereas adjoining 
portal triads may be normal. Even with these reserva- 
tions we suggest that biochemical determinations in the 
transplanted liver should be interpreted from a new 
perspective. By implication, newer, noninvasive 
methods of monitoring liver allografts may need to be 
developed. 
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